What is Lu PSMA (Lutetium-Prostate Specific Membrane Antigen) Therapy?

Lu177 PSMA Therapy is a treatment for patients with prostate cancer, especially those who have become refractory to conventional therapy. Lutetium PSMA therapy helps to slow down the growth of the cancer cells, reduce the size of the tumours and most importantly improve the quality of life of the patients by reducing the pain caused by the cancer.

Many prostate cancers, in particular those that have spread or become resistant to hormonal therapies, express a unique receptor on their cell surface called Prostate Specific Membrane Antigen (PSMA). When Prostate Cancer metastasizes i.e. spreads to other parts of the body, the PSMA receptor is expressed over the sites of metastases as well.

How does Lu PSMA Therapy Work?

Lutetium-177 is a radioactive substance that emits beta radiation, a destructive kind of radiation. Lutetium-177 is bound to a small peptide which attaches to the PSMA receptor expressed on the cancer cell surface. The Lutetium 177 – PSMA complex, thus attached to the prostate cancer cell, then emits killing radiation causing cell death of the cancer cell. Since the penetration of the emitted beta particle is very small, the surrounding normal cells are spared.

How is the Therapy Done?

Lu177 PSMA is administered intravenously. The patient is admitted to the hospital for 24 hours. A kidney function scan called a MAG3/EC scan is done prior to the administration of the Lu177 PSMA.

What are the Side Effects of Lu PSMA Therapy?

Lu177 PSMA is well tolerated. The most common side effects are a slightly dry mouth, fatigue and nausea. There may also be a slight fall in the white blood cells and platelets about 2 – 3 weeks after the Lu177 PSMA administration.

What is the Response Rate With Lu PSMA Therapy?

The response rates of Lu177 PSMA depend on the tumour biology of prostate cancer, the initial Gleason Score, the extent of disease and the responses to prior therapies. Typically, more than 70% of patients demonstrate a reduction in S. PSA and a shrinkage of tumours following Lu177 PSMA therapy.

When would the doctor consider using this Therapy?

Lu PSMA Therapy is a very specific therapy and is used for managing metastatic Prostate Cancer or when Prostate Cancer is no longer responsive to other types of treatment.

What are the Treatment Schedules with Lu PSMA Therapy?

Most patients undergo three-four treatment cycles at intervals of 8-12 weeks. The number of cycles and the interim duration may vary between individuals depending on the response and interim assessments.

Why should I choose the nuclear medicine therapy center at Fortis Memorial & Research Institute (FMRI), Gurugram (Haryana, India)?

The Nuclear Medicine Therapy Centre at FMRI was one of the first institutes to offer Radio-ligand Therapy with Lu PSMA, and today, the center receives patients from the country and from across the world.

Lutetium-177 PSMA Therapy for Metastatic Prostate Carcinoma

PATIENT ONCOLOGY HISTORY

Age: 77-Year-Old Male
Diagnosis: Metastatic Prostate Carcinoma.
Previous Treatments: The patient has not received any previous treatments.

Clinical Assessment before treatment procedure: Left leg weakness and left hip pain with some muscle wasting in the arms and legs.

TREATMENT PROCEDURES

The patient was counseled regarding his extensive metastatic disease, including possible bone marrow involvement with the risk of relatively poorer outcomes in view of the disease’s extent. The treatment options, potential benefits of 177 Lu PSMA therapy of tumor control and pain relief, complications and side effects including possible bone marrow suppression potentially requiring multiple Packed RBC or platelet transfusions, GCSF injections, and hospital or ICU admissions and in rare cases life-threatening neutropenia and thrombocytopenia were explained to the patient. The potential adverse effects of a dry mouth were also discussed.

Infusion: Lutetium PSMA Therapy

The patient received Two doses of 177Lu DKFZ-PSMA-617 at an interval of 08 week by slow intravenous infusion using renal protection protocol (Hydration with intravenous normal saline).

Clinical Assessment: The patients PSA levels dropped significantly and the PSMA PET CT scan done for treatment response assessment demonstrated a good partial response with a significant reduction in PSMA uptake in most of the lesions

The patient reported that left shoulder & left hip pain is significantly reduced. The patient has no complaints of dry mouth or any other side effects. His appetite and overall general condition have improved.

Consult Dr Ishita B Sen

Your Name (required)

Your Email (required)

Phone Number (required)

Upload your Reports(Max file size 20mb)

Medical History

captcha

[Type Security code here]

Lutetium 177 PSMA Therapy as the first line of treatment for Metastatic Prostate Carcinoma

PATIENT ONCOLOGY HISTORY

TREATMENT PROCEDURES

Infusion: Lutetium PSMA Therapy

Also Read

Consult Dr Ishita B Sen